证券代码：600351 证券简称：亚宝药业 公告编号：2023-038 地址：山西省太原经济技术开发区大运路 20 号 8、原药品批准文号：国药准字 H14023995 9、审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品 医疗器械审评审批制度的意见》（国发〔2015〕44 号）和《关于仿制药质量和疗 效一致性评价工作有关事项的公告》（2017 年第 100 号）的规定，经审查，本品 视同通过仿制药质量和疗效一致性评价。同意本品处方及生产工艺、质量标准的 变更，有效期为 18 个月。 亚宝药业集团股份有限公司 关于全资子公司获得药品补充申请批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）全资子公司亚宝药 业太原制药有限公司（以下简称"太原制药"）收到了国家药品监督管理局（以 下简称"国家药监局"）核准签发的关于诺氟沙星胶囊的《药品补充申请批准通 知书》（通知书编号：2023B05014），该药品视同通过仿制药质量和疗效一致性评 价。现将相关情 ...

截至 2023 年 9 月 28 日，公司通过集中竞价交易方式已累计回购股份 14,148,600 股，占公司总股本的比例为 1.84%，回购的最高成交价为 7.19 元/ 股，最低成交价为 6.89 元/股，支付的总金额为人民币 100,021,873.5 元（不含 交易费用）。 证券代码：600351 证券简称：亚宝药业 公告编号：2023-037 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份的基本情况 亚宝药业集团股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日召开 2023 年第一次临时股东大会，审议通过了《关于以集中竞价交易方式回购股份 的议案》，同意公司使用自有资金以集中竞价方式回购公司股份，回购股份的资 金总额不低于人民币 1.5 亿元（含）且不超过人民币 3 亿元 （含），回购股份价 格不超过人民币 7.20 元/股，回购用途为全部予以注销并减少公司注册资本， 回购期限为自股东大会审议通过回购方案之日起不超过 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2023-036 亚宝药业集团股份有限公司 关于参与投资杭州华方丰柏投资管理合伙企业（有 限合伙）新增有限合伙人及增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资标的名称：杭州华方丰柏投资管理合伙企业（有限合伙） 总投资金额：由 20,005 万元增至 45,000 万元人民币（认缴出资，具体 以实际出资金额为准） 新增有限合伙人：杭州高科技创业投资管理有限公司、浙江美澳投资管 理有限公司、鄂州临空发展产业基金合伙企业（有限合伙）、杭州泰鲲股权投资 基金合伙企业（有限合伙）、华立集团股份有限公司、台州银章瑜沅投资合伙企 业（有限合伙）。 一、 对外投资概述 亚宝药业集团股份有限公司（以下简称"公司"）于 2022 年 8 月 19 日与各 合伙人签署了《杭州华方丰柏投资管理合伙企业（有限合伙）合伙协议》，公司 作为有限合伙人（LP）参与杭州华方丰柏投资管理合伙企业（有限合伙）（以下 简称"华方丰柏"或"合伙企业"），公司以自有资金认缴出 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600351 证券简称：亚宝药业 公告编号：2023-035 一、2023 年 1 至 8 月主要经营数据 亚宝药业集团股份有限公司 2023 年 1 至 8 月主要经营数据公告 特此公告。 亚宝药业集团股份有限公司董事会 2023 年 9 月 27 日 1 2023年1至8月，经亚宝药业集团股份有限公司（以下简称"公司"）初步 核算，公司实现营业收入19.20亿元左右，同比增长13.10%左右；实现归属于上 市公司股东的净利润1.94亿元左右，同比增长114.91%左右。 二、说明事项 （一）上述主要经营数据为初步核算数据，仅作为阶段性财务数据供投资 者参考，不能以此推算公司全年业绩情况，敬请投资者理性投资，注意风险。 （二）《中国证券报》、《上海证券报》以及上海证券交易所网站 （http://www.sse.com.cn）为公司指定的信息披露报刊和网站，公司发布的信 息以在上述指定报刊和网站刊登的公告为准。 ...

证券代码：600351 证券简称：亚宝药业 公告编号： 2023-034 亚宝药业集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日(星期四) 上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 07 日(星期四) 至 09 月 13 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wangyu@yabaoyaoye.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 亚宝药业集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 23 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经营成果 ...

一、回购股份的基本情况 亚宝药业集团股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日召开 2023 年第一次临时股东大会，审议通过了《关于以集中竞价交易方式回购股份 的议案》，同意公司使用自有资金以集中竞价方式回购公司股份，回购股份的资 金总额不低于人民币 1.5 亿元（含）且不超过人民币 3 亿元 （含），回购股份价 格不超过人民币 7.20 元/股，回购用途为全部予以注销并减少公司注册资本， 回购期限为自股东大会审议通过回购方案之日起不超过 12 个月，具体内容详见 公司于 2023 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn）及《中国证 券报》、《上海证券报》上发布的《亚宝药业集团股份有限公司关于以集中竞价交 易方式回购股份的回购报告书》（公告编号：2023-010）。 二、回购股份的进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司股份回购进展情况公告如下： 截至 2023 年 8 月 31 日，公司通过集中竞价交易方式已累计回购股份 14,148,600 股，占公司总股本的比例为 1. ...

Financial Performance - The company's operating revenue for the first half of 2023 reached RMB 1,532,836,354.03, representing an increase of 18.46% compared to the same period last year[19]. - The net profit attributable to shareholders of the listed company was RMB 168,027,465.72, a significant increase of 67.35% year-on-year[19]. - The net profit after deducting non-recurring gains and losses was RMB 159,099,792.27, reflecting a growth of 71.37% compared to the previous year[19]. - The net cash flow from operating activities was RMB 254,736,109.40, up by 32.53% from the same period last year[19]. - Basic earnings per share for the first half of 2023 were RMB 0.2182, up 67.33% year-on-year[21]. - The diluted earnings per share also stood at RMB 0.2182, reflecting the same growth rate of 67.33%[21]. - The weighted average return on net assets increased to 5.51%, up by 2.13 percentage points from the previous year[21]. - The company achieved operating revenue of 1.533 billion yuan, representing a year-on-year growth of 18.46%[41]. - The net profit attributable to shareholders reached 168 million yuan, with a year-on-year increase of 67.35%[41]. - The company reported a total comprehensive income of 111,204,884 CNY for the current period, indicating a positive performance[139]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 4,022,110,083.26, a decrease of 2.64% compared to the end of the previous year[19]. - The net assets attributable to shareholders of the listed company increased to RMB 3,029,008,258.66, marking a growth of 1.98% from the previous year[19]. - Total liabilities decreased to ¥765,374,700.55 from ¥891,868,182.98, showing improved financial stability[111]. - The total liabilities at the end of the reporting period are 1,151,886,341.30 RMB, which represents a stable financial position[134]. - The company's total current assets as of June 30, 2023, amounted to CNY 1,868,939,563.08, a decrease from CNY 1,954,333,997.61 at the end of 2022, reflecting a decline of approximately 4.37%[105]. Research and Development - The company has established research institutes in Beijing, Shanxi, Suzhou, and the United States, enhancing its R&D capabilities[39]. - The company has developed multiple core technologies, including transdermal drug delivery systems and automated production lines for traditional Chinese medicine injections[40]. - Research and development expenses increased to ¥51,797,296.07, up from ¥48,120,429.42, indicating a focus on innovation[113]. - The company plans to enhance its research and development capabilities to mitigate risks associated with drug development, which is characterized by high costs and long cycles[61]. - The company is focused on research and development to better inherit and promote traditional Chinese medicine culture[29]. Market Strategy and Product Development - The company has been focusing on the development of traditional Chinese medicine, which is supported by national policies aimed at revitalizing the industry[27]. - The company aims to strengthen its market position through continuous innovation and adaptation to policy changes in the healthcare sector[29]. - The company is focused on expanding its market presence through strategic partnerships and a comprehensive distribution network[34]. - The company has over 300 products covering various therapeutic areas including pediatrics, pain relief, cardiovascular, endocrine, digestive, and more[30]. - The company is committed to improving its product portfolio and enhancing its core competitiveness in the traditional Chinese medicine market[29]. Environmental Compliance - The company has established a wastewater treatment plant with a design capacity of 300 tons per day, currently treating approximately 100 tons of wastewater daily[79]. - The wastewater treatment facility at the company operates continuously and meets the discharge standards set by the Tianfu Traditional Chinese Medicine City Management Committee[79]. - The company has installed online monitoring devices for COD and ammonia nitrogen at its wastewater discharge points, ensuring compliance with environmental standards[77]. - The company’s emissions of non-methane total hydrocarbons and other volatile organic compounds are within the regulatory limits, with no exceedance reported[76]. - The company adheres to the environmental impact assessment system for construction projects, ensuring compliance with environmental regulations[80]. Shareholder and Governance - The company held its annual general meeting on May 18, 2023, where it approved several key resolutions, including the election of new board members[69]. - As of the end of the reporting period, the total number of ordinary shareholders was 51,623[95]. - The largest shareholder, Shanxi Yaobao Investment Group Co., Ltd., holds 94,300,000 shares, representing 12.25% of the total shares, with 46,700,000 shares pledged[97]. - The company has a registered capital of CNY 5 billion across its subsidiaries, indicating a strong financial foundation for future growth[59]. Financial Management - The financial audit for the first half of 2023 was conducted by Crowe Horwath, with an audit fee of RMB 650,000 and an internal control audit fee of RMB 300,000[87]. - The company reported a significant increase in prepayments, rising to CNY 84,588,959.41 from CNY 46,417,277.50, which is an increase of approximately 82%[105]. - The company has completed three generic drug registration applications and two product responses during the reporting period[43]. - The company has implemented a comprehensive quality management system in line with FDA-cGMP standards to ensure product quality[36]. - The company has reported a decrease in financial expenses to ¥3,549,440.12 from ¥5,800,352.30, suggesting better cost management[113].

亚宝药业集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600351 证券简称：亚宝药业 公告编号：2023-024 重要内容提示： 投资者可于 2023 年 05 月 23 日(星期二) 至 05 月 29 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 guanjiajia@yabaoyaoye.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 亚宝药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发 布公司 2022 年年度报告和 2023 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 05 月 30 日上午 10:00-11:00 举行 2022 年度暨 2023 年第一季度业绩说明会， 就投资者关心的问题进行交流。 一、 说明会类型 本次投 ...

Financial Performance - In 2022, the company's operating revenue was CNY 2,718,134,785.52, a decrease of 1.66% compared to CNY 2,763,962,481.58 in 2021[23] - The net profit attributable to shareholders of the listed company for 2022 was CNY 104,655,073.39, down 44.06% from CNY 187,089,423.86 in 2021[23] - The net profit after deducting non-recurring gains and losses was CNY 87,401,669.09, a decrease of 37.71% compared to CNY 140,304,645.66 in the previous year[23] - Cash flow from operating activities for 2022 was CNY 460,462,582.82, an increase of 5.25% from CNY 437,503,470.18 in 2021[23] - Basic earnings per share decreased by 44.07% to 0.1359 yuan per share in 2022 compared to 0.2430 yuan per share in 2021[25] - The weighted average return on equity fell to 3.56%, a decrease of 3.01 percentage points from 6.57% in 2021[25] Assets and Dividends - The total assets at the end of 2022 were CNY 4,131,067,057.38, reflecting a 1.33% increase from CNY 4,076,677,070.74 at the end of 2021[24] - The net assets attributable to shareholders of the listed company at the end of 2022 were CNY 2,970,077,495.32, up 1.47% from CNY 2,926,964,820.93 at the end of 2021[24] - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares, totaling CNY 38,500,001.15, based on a total share capital of 770,000,023 shares[6] Strategic Focus and R&D - The company focused on pediatric products, generic drugs, and innovation investments as part of its strategic direction[30] - The company plans to enhance R&D efficiency and accelerate the introduction of new products in pediatric and chronic disease sectors[31] - The company is committed to a "Pediatric First" strategy, focusing on innovative marketing and channel transformation to enhance product development and service models[34] - The company’s research and development efforts are aligned with national strategies to promote health and traditional medicine, aiming for high-quality development in the pharmaceutical sector[38] - The company aims to strengthen its market position in the traditional Chinese medicine sector, focusing on proprietary and specialty products, with an emphasis on pediatric traditional Chinese medicine[41] Market Performance - The company’s OTC sales segment saw a market share increase for its flagship product Dinggui Er Qi贴, reaching 17.8%, a year-on-year increase of 0.8 percentage points, while sales for Yiyang Jianpi Gel reached 55.26 million yuan, a 42% year-on-year growth[35] - RX sales for the company’s pediatric products, particularly the Children's Throat Relief Oral Liquid, achieved 80.65 million yuan in revenue, a 89% year-on-year increase, amidst a competitive procurement environment[36] - The company’s brand exposure reached a historical high of 12.2 billion in 2022, enhancing brand visibility through various marketing strategies[36] Cost Management and Efficiency - The production center optimized production processes and implemented cost management to improve efficiency and reduce costs[31] - The company's sales expenses decreased by 13.98% to 897 million RMB, attributed to a reduction in marketing expenses[55] - Research and development expenses fell by 16.87% to 131 million RMB, reflecting a decrease in R&D investment[55] - The company’s operating costs rose by 11.35% to 1.199 billion RMB, mainly due to increased costs in pharmaceutical wholesale[55] Regulatory and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[8] - The company has not proposed any stock issuance or capital reserve transfer to increase share capital for the year 2022[6] - The company strictly adheres to information disclosure regulations, ensuring timely, fair, and accurate information is available to all shareholders[124] - The company has not experienced significant differences in governance compared to regulatory requirements, ensuring compliance[125] Environmental Responsibility - The company invested CNY 8.9 million in environmental protection initiatives during the reporting period[159] - The wastewater treatment station at Ruicheng Industrial Park has a daily processing capacity of 1,000 tons, utilizing hydrolysis acidification and anaerobic tower biological oxidation processes, meeting the GB21905-2008 standard for pharmaceutical wastewater discharge[166] - The company has implemented a comprehensive pollution prevention strategy, including the construction of advanced wastewater treatment facilities and the installation of emission monitoring systems[166][167] Governance and Management - The company has a supervisory board consisting of 3 members, including 1 employee representative, complying with relevant laws and regulations[123] - The performance evaluation of senior management is conducted annually by the Compensation and Assessment Committee, ensuring accountability[123] - The company’s board of directors and senior management have maintained stable shareholdings, with no changes reported during the period[129] - The company has established a structured remuneration system for its directors and senior management, ensuring alignment with performance evaluations[136]

Financial Performance - The company's operating revenue for Q1 2023 was ¥800,499,169.06, representing a year-on-year increase of 15.30%[5] - The net profit attributable to shareholders for the same period was ¥107,419,836.15, reflecting a significant increase of 50.47% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.1395, which is an increase of 50.47% year-on-year[6] - Total revenue for Q1 2023 reached ¥800,499,169.06, an increase of 15.3% compared to ¥694,295,635.07 in Q1 2022[17] - Operating profit for Q1 2023 was ¥130,496,444.86, up 48.4% from ¥87,848,278.81 in Q1 2022[18] - Net profit for Q1 2023 was ¥108,529,546.66, representing a 55% increase from ¥70,043,628.72 in Q1 2022[18] - Earnings per share for Q1 2023 were ¥0.1395, compared to ¥0.0927 in Q1 2022, reflecting a growth of 50.5%[19] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥94,425,180.27, marking an impressive increase of 88.76% year-on-year[5] - Operating cash inflow for Q1 2023 was CNY 699,369,435.86, an increase of 16.1% from CNY 602,384,142.98 in Q1 2022[20] - Net cash flow from operating activities for Q1 2023 was CNY 94,425,180.27, up 88.5% from CNY 50,025,100.38 in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 711,175,799.49, compared to CNY 481,228,091.53 at the end of Q1 2022, representing a 47.7% increase[22] - The company reported a cash balance of RMB 761,097,151.88, up from RMB 668,503,421.96, indicating stronger liquidity[13] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,212,374,707.12, a 1.97% increase from the end of the previous year[6] - The total current assets amounted to RMB 2,060,915,179.43, an increase from RMB 1,954,333,997.61 as of December 31, 2022[13] - The total non-current assets decreased to RMB 2,151,459,527.69 from RMB 2,176,733,059.77, indicating a reduction in long-term investments[14] - Total liabilities increased to RMB 2,060,915,179.43, reflecting the company's ongoing financing activities[14] - Total liabilities decreased to ¥1,097,217,381.19 in Q1 2023 from ¥1,124,425,007.43 in Q1 2022, a reduction of approximately 2.4%[17] - Total equity increased to ¥3,115,157,325.93 in Q1 2023 from ¥3,006,642,049.95 in Q1 2022, marking a growth of about 3.6%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 56,133[11] - The largest shareholder, Shanshi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 12.25% of total shares[11] Expenses and Cost Management - Research and development expenses for Q1 2023 were ¥27,263,743.67, up from ¥25,593,278.84 in Q1 2022, indicating a 6.5% increase[17] - Sales expenses rose to ¥238,759,501.81 in Q1 2023, compared to ¥223,202,616.75 in Q1 2022, reflecting a growth of 7%[17] - The company reported a significant reduction in sales expenses, which decreased to ¥11,538,915.78 from ¥13,592,317.90 in Q1 2022, indicating improved cost management[25] - The company reported a decrease in financial expenses to ¥2,250,799.69 in Q1 2023 from ¥3,876,165.30 in Q1 2022, a reduction of approximately 42%[17] Government Subsidies - The company reported a significant increase in government subsidies recognized in profit or loss, which rose by 226.50% year-on-year[9] - Other income for Q1 2023 was ¥8,034,006.80, significantly higher than ¥2,460,643.90 in Q1 2022, representing a growth of 226.5%[17] Future Plans - The company plans to continue expanding its market presence and investing in new product development[25] - The company has not reported any significant new product developments or market expansions in the current quarter[12]